Autoimmune Neurology: Overview & Diagnostic Approach
Autoimmune neurology is a rapidly expanding subspecialty dedicated to neurologic disorders caused by aberrant immune responses against neural self-antigens. These conditions are typically diagnosable through disease-specific neural IgG antibody biomarkers detected in serum, CSF, or both. The field has undergone a dramatic transformation over the past two decades, with the identification of more than 20 disease-associated antibodies, each linked to recognizable clinical syndromes. Because these disorders are potentially treatable with immunotherapy, autoimmune neurology now represents a critical "not to miss" category in contemporary neurologic practice.
Bottom Line
- Subacute onset: Most autoimmune neurologic disorders present with rapid progression to significant impairment within days to 12 weeks
- Two antibody categories: Intracellular antigen antibodies (T-cell effectors, paraneoplastic, poor immunotherapy response) vs. cell-surface antigen antibodies (antibody-mediated, often better response)
- Incidence: Autoimmune encephalitis (~1.2/100,000/year) is now comparable to infectious encephalitis in high-income countries
- Phenotype-based testing: Antibody panels guided by neurologic phenotype are recommended over broad, undirected screening
- CSF + serum: Both should be tested; CSF confers higher specificity, serum has higher sensitivity
- Early treatment: Prompt immunotherapy (corticosteroids, IVIg, PLEX) is recommended, supplemented by immune suppressants (rituximab, cyclophosphamide) for sustained response
Epidemiology and Risk Factors
The incidence of autoimmune neurologic disorders has increased over time, primarily attributable to improved recognition through sensitive and specific antibody testing.
| Disorder | Incidence/Prevalence | Key Demographics |
|---|---|---|
| Autoimmune encephalitis (overall) | 1.2/100,000 person-years | African Americans disproportionately affected |
| NMDA receptor encephalitis | Exceeds HSV encephalitis in patients ≤35y | F:M 4:1; Pacific Islander, Māori, Asian backgrounds |
| LGI1 encephalitis | ~1–2 per million/year (most common overall) | M:F 2:1; predominantly White and Asian; median age ~65 |
| Paraneoplastic neurologic syndromes | 0.8/100,000 person-years | Prevalence 5.4/100,000 |
| AQP4-IgG+ NMOSD | <1/million/year (White); higher in Asian and Black populations | F:M 8:1 |
Risk Factors
- Age: NMDA receptor encephalitis peaks in children/young adults; LGI1 encephalitis typically after age 60
- Sex: Female predominance in NMDA receptor encephalitis (1:4 M:F) and NMOSD (1:8); male predominance in LGI1 and CASPR2 encephalitis
- HLA associations: Found for IgG4-dominant disorders (LGI1: HLA-DRB1*07:01; CASPR2: HLA-DRB1*11:01; IgLON5, KLHL11)
- Cancer: Tumor-expressed neural antigens trigger paraneoplastic autoimmunity; immune checkpoint inhibitors can trigger autoimmunity
- Infection: Post-HSV-1 encephalitis can trigger NMDA receptor (and other) antibodies through antigen release on neuronal death
- Personal/family autoimmune history: Particularly relevant for GAD65 autoimmunity
Pathophysiology
Two Categories of Neural Antibodies
| Feature | Intracellular Antigen Antibodies | Cell-Surface Antigen Antibodies |
|---|---|---|
| Effector mechanism | CD8+ cytotoxic T cells | Antibody-mediated (IgG) |
| Antibody role | Biomarker only (not directly pathogenic) | Directly pathogenic |
| Tissue damage | Irreversible neuronal death | Often reversible receptor dysfunction |
| Cancer association | High (most are paraneoplastic) | Variable (low for LGI1/CASPR2; high for GABAB) |
| Immunotherapy response | Often poor; cancer treatment may be more important | Often good |
| Examples | ANNA-1 (Hu), PCA-1 (Yo), KLHL11, Ma2, GAD65, GFAP | NMDA-R, LGI1, CASPR2, GABAB, GABAA, AQP4, MOG |
Pathogenic Mechanisms of Cell-Surface Antibodies
- Receptor internalization (modulation): IgG cross-links and internalizes receptors, reducing cell-surface density (NMDA-R, AMPA-R, GABAA-R)
- Direct functional inhibition: Impairs receptor function without internalization (GABAB-R)
- Protein-protein interaction disruption: Interferes with target's function; predominant in IgG4-mediated diseases (LGI1 disrupts LGI1-ADAM22 interaction)
- Complement activation: Membrane attack complex formation, causing cell lysis (AQP4-NMOSD)
- Antibody-dependent cellular cytotoxicity: Also implicated in AQP4 immunity
Clinical Presentations
Autoimmune neurologic disorders are almost always subacute in onset (days to weeks, with significant impairment by 6–12 weeks) and rapidly progressive. Any level of the neuroaxis may be affected. Key clinical presentations include:
Recognizable Phenotypes
- Limbic encephalitis: Subacute amnesia, seizures, behavioral changes; mesial temporal T2/FLAIR hyperintensity (LGI1, GABAB, AMPA, ANNA-1)
- Encephalitis with movement disorder: Polymorphic movement disorder, psychiatric features, autonomic dysfunction, coma (NMDA-R)
- Faciobrachial dystonic seizures: Pathognomonic brief dystonic posturing of arm/face, hundreds/day (LGI1)
- Progressive encephalomyelitis with rigidity and myoclonus: Startle, stiffness, brainstem dysfunction (glycine receptor)
- Rapidly progressive cerebellar ataxia: Often paraneoplastic (PCA-1/Yo, ANNA-1/Hu)
- Stiff person syndrome: Axial rigidity, spasms (GAD65, amphiphysin, glycine receptor)
- Optic neuritis / myelitis: Demyelinating syndromes (AQP4, MOG)
- Peripheral nerve hyperexcitability: Neuromyotonia, fasciculations (CASPR2, Morvan syndrome)
Diagnostic Approach
When to Suspect Autoimmune Etiology
- Subacute onset of neurologic dysfunction (days to weeks)
- Multifocal or atypical presentation without a clear structural or metabolic cause
- CSF showing inflammatory markers (pleocytosis, elevated protein, oligoclonal bands)
- MRI showing T2/FLAIR hyperintensity in characteristic patterns (mesial temporal, radial perivascular)
- History of cancer, recent immune checkpoint inhibitor use, or recent HSV encephalitis
- Personal or family history of autoimmune disease
Antibody Testing Principles
Optimal Testing Strategy
- Send both CSF and serum to diagnostic laboratories for all suspected autoimmune encephalitis
- CSF: High specificity, low false-positive rate; preferred for NMDA-R antibodies
- Serum: High sensitivity but higher false-positive rate, particularly for MOG and CASPR2
- Phenotype-based panels: Order antibody panels guided by the neurologic phenotype rather than broad, undirected screening
- Complementary assays: Cell-based assays (live or fixed) plus tissue-based assays reduce false-positive rates over single-assay methods
- Longitudinal titers: Not proven valuable for monitoring disease status — clinical assessment is the preferred metric
- Expert consultation: Discuss results with an autoimmune neurology expert, especially if they do not fit the clinical scenario
Diagnostic Pitfalls
- False positives: Low-positive titers, especially in serum alone, carry risk of misdiagnosis and inappropriate immunotherapy
- Voltage-gated potassium channel (VGKC) antibodies: This legacy assay has been largely abandoned; results not specific to LGI1 or CASPR2 should be interpreted cautiously
- GAD65: Low titers (<20 nmol/L) are common in the general population (diabetes); only high titers with compatible phenotype are diagnostically significant
- Seronegative autoimmune encephalitis: Exists and may respond to immunotherapy; absence of antibodies does not exclude the diagnosis
Paraclinical Evaluation
| Investigation | Key Findings | Relevant Syndromes |
|---|---|---|
| Brain MRI | Mesial temporal T2/FLAIR hyperintensity; multifocal cortical/subcortical lesions; radial perivascular enhancement; normal in many cases | LGI1 (40% temporal); GABAA (multifocal); GFAP (radial); NMDA-R (often normal) |
| CSF | Lymphocytic pleocytosis; elevated protein; oligoclonal bands; intrathecal antibody synthesis | NMDA-R (80% abnormal); GABAB (80%); LGI1 (only 25%) |
| EEG | Slowing, epileptiform activity, extreme delta brush pattern | NMDA-R (90% abnormal); GABAB (75% ictal); LGI1 (50%) |
| EMG | Peripheral nerve hyperexcitability: fasciculations, myokymic discharges, neuromyotonia | CASPR2/Morvan syndrome (60%) |
| CT body / PET-CT | Cancer screening; teratoma, SCLC, thymoma, breast/ovarian cancer | All paraneoplastic antibodies; NMDA-R (teratoma); GABAB (SCLC) |
Cancer Screening
Risk factors that should be considered when evaluating autoimmune neurologic disorders include cancer history, smoking history, other autoimmune disease history, and immune checkpoint inhibitor use. Specific cancer associations guide screening:
- NMDA-R: Ovarian teratoma in ~60% of females aged 15–35; screening in children and males is less urgent
- ANNA-1 (Hu), CRMP-5, SOX1: ~80–90% associated with SCLC
- PCA-1 (Yo): ~90% with breast, ovarian, or mullerian cancer
- KLHL11, Ma2, LUZP4: Germ cell tumors (seminoma)
- GABAB: ~50% with SCLC
- CASPR2/Morvan: ~20–25% with thymoma
- LGI1: Rare cancer association (<10%)
General Treatment Principles
| Line | Therapies | Notes |
|---|---|---|
| First-line | IV methylprednisolone, IVIg, plasma exchange | Early initiation recommended; can be combined |
| Second-line | Rituximab, cyclophosphamide | For non-responders or to sustain response; rituximab preferred for cell-surface antibody syndromes |
| Maintenance | Rituximab, mycophenolate, azathioprine, periodic IVIg | Reduce relapse risk; duration individualized |
| Tumor treatment | Surgical resection, chemotherapy, radiation | Critical for paraneoplastic disorders; may be the most effective intervention |
Treatment response differs fundamentally between the two antibody categories: cell-surface antibody syndromes typically show better immunotherapy response (reflecting the reversible nature of antibody-mediated dysfunction), while intracellular antigen syndromes often respond poorly (reflecting irreversible T-cell-mediated neuronal death). For intracellular antigen/paraneoplastic disorders, tumor removal and agents targeting T cells (cyclophosphamide, mycophenolate) may be more effective than B-cell-directed therapies.
References
- McKeon A, Pittock SJ. Overview and diagnostic approach in autoimmune neurology. Continuum (Minneap Minn). 2024;30(4):960-994.
- Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391-404.
- Dubey D, Pittock SJ, Kelly CR, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol. 2018;83(1):166-177.
- Flanagan EP, Geschwind MD, Lopez-Chiriboga AS, et al. Autoimmune encephalitis misdiagnosis in adults. JAMA Neurol. 2023;80(1):30-39.